Table 4.

Regression models assessing odds of overall and GU-specific complications after MMC therapy (values bolded if p < 0.05)

	Total Complications (n=63)		GU Complications (n=55)
Covariate	Unadjusted OR (95% CI)	Adjusted OR† (95% CI)	Unadjusted OR (95% CI)	Adjusted OR† (95% CI)
Administration of MMC	2.12 (1.17 – 3.86)	2.89 (1.43–5.81)	1.54 (0.84 – 2.84)	1.82 (0.92 – 3.61)
Pathologic stage ‡
T0	0.18 (0.05 – 0.63)	0.15 (0.04 – 0.55)	0.23 (0.07 – 0.78)	0.21 (0.06 – 0.75)
T1	0.57 (0.22 – 1.51)	0.62 (0.22 – 1.78)	0.56 (0.20 – 1.58)	0.60 (0.20 – 1.75)
T2	0.21 (0.05 – 0.95)	0.22 (0.04 – 1.13)	0.26 (0.06 – 1.18)	0.32 (0.07 – 1.57)
Prior radiation therapy	0.42 (0.12 – 1.47)	0.51 (0.13 – 1.95)	0.51 (0.14 – 1.79)	0.62 (0.17 – 2.32)
Treatment at outside institution	0.40 (0.15 – 1.07)	0.23 (0.07 – 0.73)	0.49 (0.18 – 1.32)	0.36 (0.12 – 1.09)

Abbreviations: GU – genitourinary; OR – odds ratio; CI – confidence interval; MMC – mitomycin-C

^†Model includes the above covariates and adjusts for age and year of operation

^‡Reference group is stage Ta/Tis